(Natural News) Senior officials working in the White House are strongly objecting to the standards put forward by the Food and Drug Administration (FDA) that will determine whether or not a Wuhan coronavirus (COVID-19) vaccine is ready for public distribution.
People familiar with the situation are telling news outlets like the Wall Street Journal that it is unlikely that the White House will sign off on the agency's proposed guidelines. The officials have expressed unhappiness with several factors, including one proposal that would require companies to monitor trial subjects for side effects for at least two months after they receive the vaccine. This represents a serious breach of personal privacy, and the White House would like the FDA to scrap the plan altogether.
Among the officials that have raised concerns are White House Chief of Staff Mark Meadows and many officials and aides working for the Office of Management and Budget (OMB)
While there is a chance that Meadows, the OMB and the FDA can come to an understanding, recent talks between the White House and the FDA have failed to indicate that they have agreed on a resolution to the conflict.
The FDA has made it clear that they do not need the approval of the White House before proceeding. However, they do want the administration's blessing in order to reassure Americans that the vaccines the FDA approves will meet the supposedly high standards that they have set for vaccine manufacturers.
Many Americans are already rightfully concerned about the arrival of coronavirus vaccines due to the speed with which corporations are trying to get them into public use. This is raising concerns about the safety of the shots. The fact that the FDA wants people who take them to be monitored for two months after the vaccination date will likely only bring in more skepticism to the whole affair.